The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers

@inproceedings{Liu2014TheIO,
  title={The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers},
  author={Yong Liu and Simon Y Zhou and Yuntao Wan and Anfan Wu and Maria Palmisano},
  booktitle={British journal of clinical pharmacology},
  year={2014}
}
AIMS Two clinical studies were conducted to determine possible drug-drug interactions between apremilast and a strong CYP3A4 inhibitor, ketoconazole, or a potent CYP3A4 inducer, rifampicin. The main objectives of these two studies were to evaluate the impact of multiple doses of ketoconazole on the pharmacokinetics of apremilast and its metabolites, and the effect of multiple oral doses of rifampicin on the pharmacokinetics of apremilast. METHODS These single centre, open label, sequential… CONTINUE READING
BETA
3
Twitter Mentions

Similar Papers

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: results of a phase 2 randomised study

K Papp, J Cather, +5 authors RM. Day
  • Lancet
  • 2012

Absolute bioavailability of apremilast using a [ 14 C ] labeled microtracer IV solution concomitantly with an oral dose [ abstract ]

A Wu, Y Wan, +5 authors M Palmisano
  • Guidance for industry : drug interaction studies - study design , data analysis , implications for dosing , and labeling recommendations
  • 2011

First - time - inman , safety / tolerability and pharmacokinetics of ascending oral doses of apremilast ( APR ) in healthy subjects ( HS ) [ abstract 515 ]

A Wu, M Scheffler
  • J Invest Dermatol
  • 2011